SCHEMBL2561709

SCHEMBL2561709

NC(=O)c1cnc2ncncc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMD14 O00487 1/20 0.46
STAMBP O95630 1/20 0.46
COPS5 Q92905 1/20 0.46
HPGDS O60760 1/20 0.42
NNMT P40261 7/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
VNN1 O95497 1/20 0.36
CHEK2 O96017 1/20 0.36
SIRT2 Q8IXJ6 3/20 0.35
SIRT1 Q96EB6 3/20 0.35
SIRT3 Q9NTG7 3/20 0.35
F7 P08709 1/20 0.35
F3 P13726 1/20 0.35
SARM1 Q6SZW1 1/20 0.35
SIRT6 Q8N6T7 1/20 0.35
SIRT5 Q9NXA8 1/20 0.35
SIRT4 Q9Y6E7 1/20 0.35
AR P10275 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29755236 1.00 PSMD14 (0.46) PSMD14STAMBPCOPS5HPGDSNNMT
SCHEMBL29656527 0.84 MGAM (0.47) PSMD14
SCHEMBL1650336 0.84 MGAM (0.47) PSMD14
SCHEMBL29579636 0.82 MKNK2 (0.35) PSMD14STAMBPCOPS5VNN1
SCHEMBL28114582 0.76 PSMD14 (0.47) PSMD14STAMBPCOPS5HPGDSNNMT
SCHEMBL5676295 0.74 EGFR (0.56) HPGDSNNMTSMN1; SMN2CHEK2AR
SCHEMBL163182 0.74 PSMD14 (0.56) PSMD14STAMBPCOPS5HPGDSNNMT
Trifluoroacetic Acid SCHEMBL5265639 0.74 PSMD14 (0.45) PSMD14STAMBPCOPS5HPGDSNNMT
SCHEMBL29649950 0.74 EGFR (0.56) HPGDSNNMTSMN1; SMN2CHEK2AR
Hydrochloric Acid SCHEMBL14966721 0.72 PSMD14 (0.55) PSMD14STAMBPCOPS5HPGDSNNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011086306-A9 5-OXO-5, 8-DIHYDROPYRIDO [2, 3-D] PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES SANOFI-AVENTIS (FR) 2011-10-27 WO claimed
WO-2025128848-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2025-06-19 WO disclosed
US-11466252-B2 Expansion and differentiation of inner ear supporting cells and methods of use thereof MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2022-10-11 US disclosed
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 US disclosed
US-20220192984-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS Frequency Therapeutics, Inc. 2022-06-23 US disclosed
US-11149035-B2 Chemical compounds as H—PGDS inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED (GB) 2021-10-19 US disclosed
US-20200123152-A1 Chemical Compounds as H-PGDS Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11149035-B2 Chemical compounds as H—PGDS inhibitors HPGDS, PTGS1, PTGIS PSMD14 977/4885STAMBP 4660/4885COPS5 3176/4885
US-20200123152-A1 Chemical Compounds as H-PGDS Inhibitors HPGDS, PTGS1, PTGIS PSMD14 971/4885STAMBP 4650/4885COPS5 3199/4885
US-20220192984-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS OTC, EXOSC5, ENTPD5 PSMD14 4084/4885STAMBP 3646/4885COPS5 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.